Since tumors strongly dependent on BRAF activity did not demonstrate significant interactive cell death with DNA damage (e.g., NCI-H2405), we posited that sequential rather than concurrent treatment may optimize tumor control, limit toxicity (non-overlapping therapies) and potentially prevent treatment resistance by eradicating minimal residual disease. Here, BRAF is linked to neoplasm.